AstraZeneca/Daiichi Sankyo ADC Pact Continues Clinical Success In Breast Cancer
Early TNBC Efficacy Signs From Datopotamab Deruxtecan
While much earlier in its development, the drug may be able to rival Gilead’s Trodelvy, which also targets TROP2 and showed similar response rates.
You may also be interested in...
Gilead looks set to expand its lead position in the triple-negative breast cancer (TNBC) market in Europe with a positive opinion for Trodelvy from the CHMP.
Phase III sub-analyses presented at ESMO show the drug providing a survival benefit in a complex subpopulation, as well as improvements to quality of life.
An analyst forecast that about 40% of the drug’s sales could come from second-line disease, while lack of grade 4-5 interstitial lung disease events was seen as a plus.